Company Overview and News
Macerich's chairman and CEO, Art Coppola, is set to retire at the end of this year, having led the company for 25 years, and the news is fueling the idea that more deal activity could be looming in the retail real estate industry.
Retail might be changing, but if Sears Holdings Corp (NASDAQ:SHLD) can hang on when it’s easily the biggest mess of the mainline department stores, I have to believe that Macy’s Inc (NYSE:M) isn’t going anywhere. As retail stocks go, Macy’s stock is attractive for several reasons. Here are three I believe make it the underdog buy of the week.
The move from active to passive investing has been a secular theme for many years, and it has disrupted the asset management industry. As active fund managers face increasing pressure to outperform their benchmarks, the hunt for alpha is becoming a more difficult exercise. Some asset managers prefer to use quantitative investing techniques to construct portfolios and use machines to identify how the portfolio should behave in all facets.
April 19 (Reuters) - Bon-Ton Stores Inc won court approval on Wednesday for a bid to wind down its operations, clearing the way for one of the largest U.S. department store chains to begin selling everything from its store inventory to leases and fixtures.
April 18 (Reuters) - Bon-Ton Stores Inc won court approval on Wednesday for a bid to wind down its operations, clearing the way for one of the largest U.S. department store chains to begin selling everything from its store inventory to leases and fixtures.
Signet Jewelers (NYSE:SIG) is the largest diamond jewelry retailer in the world (Zales, Jared, Kay Jewelers and Piercing Pagoda) with over 2,500 stores worldwide. In the last year, SIG has seen sales fall somewhat and has initiated a new 3-year turnaround campaign that includes closing 200 stores.
After scouring the internet for a good amount of time, I’m convinced of one thing. Finding a bullish article on General Electric Company (NYSE:GE) is about as easy as proving Bigfoot’s existence. I know this because when I tried to look for recent bulls on GE stock, only one name came up: mine!
The broader market’s decline at the start of February has been a doozy for Home Depot Inc (NYSE:HD). After hitting a high near $207.50 in late-January, HD stock was pulverized down to $175 within just a few trading sessions. That 15.6% decline hardly seems fair, especially given that Home Depot stock still hasn’t recovered.
It’s easy to overlook small monthly expenses such as a Netflix, Inc. (NASDAQ:NFLX) or Spotify Technology SA (NYSE:SPOT) subscription. But even those small dollar amounts can add up. With the rise of discount and even free brokerages, it’s ever-easier to put small amounts of capital to work without paying exorbitant fees and buy cheap stocks.
Chicago, IL – April 13, 2018 – Zacks Equity Research highlights U.S. Steel (X - Free Report) as the Bull of the Day and Signet Jewelers Limited (SIG - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Bank of America (BAC - Free Report) , IBM (IBM - Free Report) and Pier 1 Imports (PIR - Free Report) .
Over the past five years, we’ve watched beleaguered department store J C Penney Company Inc. (NYSE:JCP) make its way steadily downward. JCP stock has nearly halved its value since April 2017 which begs the question- how much lower can J C Penney stock go?
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET